GlassScriptPhysician profile
Lawrence A Bassin
NPI 1215921473
$6,147.83
in general payments reported to CMS, 2019-2025
32 companies · $1,619 in 2025
The $1,619 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $29.95 · 2021: $78.46 · 2022: $590 · 2023: $1,765 · 2024: $1,804 · 2025: $1,619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,170 · Education: $18.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,169.75 |
| Education | $18.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,240.51 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Celgene Corporation | $645.90 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $615.37 | 2022-2025 | Entyvio, Eohilia |
| Janssen Scientific Affairs, LLC | $556.49 | 2019-2025 | Tremfya, Stelara |
| Janssen Biotech, INC. | $353.10 | 2019-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $332.49 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Celltrion USA INC. | $219.81 | 2024-2025 | Vegzelma, Zymfentra |
| Phathom Pharmaceuticals, INC. | $211.86 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $182.55 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $174.50 | 2023-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $154.05 | 2022-2025 | Ibsrela |
| Pfizer INC. | $141.77 | 2024-2025 | |
| Echosens North America, INC. | $121.00 | 2023 | Fibroscan |
| E.R. Squibb & Sons, L.L.C. | $119.70 | 2024 | |
| Gilead Sciences, INC. | $117.46 | 2024-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $117.32 | 2022-2023 | |
| Lilly USA, LLC | $116.49 | 2023-2025 | Omvoh |
| Covidien LP | $97.40 | 2019 | |
| Intercept Pharmaceuticals, INC. | $96.98 | 2023-2024 | Ocaliva |
| Madrigal Pharmaceuticals | $80.45 | 2025 | Rezdiffra |
| Boston Scientific Corporation | $72.17 | 2025 | General - Endochoice |
| Ipsen Biopharmaceuticals, INC | $54.90 | 2024 | Iqirvo |
| Braintree Laboratories, INC. | $45.20 | 2021-2023 | Sutab |
| Daiichi Sankyo INC. | $44.06 | 2025 | Injectafer |
| Genzyme Corporation | $42.53 | 2023-2024 | |
| Ironwood Pharmaceuticals, INC | $41.12 | 2023-2024 | Linzess |
| Merck Sharp & Dohme LLC | $32.94 | 2023-2024 | Dificid, Zinplava |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.10 | 2023 | Cyltezo |
| Amgen INC. | $28.61 | 2023 | Avsola, Amjevita |
| Endogastric Solutions, INC | $25.38 | 2023 | Esophyx |
| Biocon Biologics INC | $20.60 | 2025 | Yesintek |
| Ferring Pharmaceuticals INC. | $16.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Bassin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.